CEO Executive AssistantRespiratory medicine spans a wide clinical spectrum: from blockbuster asthma and COPD markets with billions of patients globally, to rare pulmonary diseases like idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and cystic fibrosis where patient populations number in the tens of thousands. Regardless of where a respiratory pharma company sits on this spectrum, the CEO faces organizational demands that require a deliberate and well-designed delegation framework.
This guide outlines how respiratory pharma CEOs can structure delegation across R&D, device and combination product development, regulatory affairs, medical affairs, and commercial operations - creating an organization that can execute with speed and expertise at every level.
The Respiratory Pharma Landscape
Respiratory pharmaceutical companies face some of the most complex product development challenges in the industry. Inhaled drug delivery requires integrated development of the active pharmaceutical ingredient and the delivery device, creating a combined product regulatory pathway with distinct requirements. Patient heterogeneity in diseases like asthma and COPD demands sophisticated biomarker-driven patient stratification strategies. And the competitive dynamics in large respiratory markets are intense, with established leaders and a steady pipeline of new entrants.
For CEOs of respiratory-focused companies, the organizational implications are significant. Device engineering, clinical pharmacology, regulatory strategy for combination products, and commercial execution in a crowded market all require dedicated expertise. CEOs who try to maintain personal involvement in these specialized functions will fall behind the competition on speed, quality, and innovation.
Harvard Business Review research confirms what many experienced pharmaceutical executives have learned through direct experience: delegating to expert teams is the highest-leverage leadership behavior available to a CEO. In the fast-moving respiratory space, this is a competitive advantage.
R&D Delegation for Respiratory CEOs
Drug and Device Development
Respiratory drug development often involves combination products - inhaled drugs delivered through metered dose inhalers, dry powder inhalers, or nebulizers. This creates an R&D function that spans pharmaceutical sciences, device engineering, and human factors research.
What to delegate:
- Formulation and device development programs
- Human factors and usability testing
- Bioequivalence and pharmacokinetic study design
- Preclinical respiratory disease model programs
- Clinical trial design and execution across all respiratory programs
- CRO and device development partner management
To whom: Chief Scientific Officer (for drug discovery and preclinical work) and Chief Medical Officer (for clinical development), with a dedicated device development function reporting to either the CSO or a VP of Device Engineering.
What the CEO retains: Portfolio strategy decisions, go/no-go milestone decisions, major partnership and licensing decisions for device or drug platform acquisition, and capital allocation across the respiratory portfolio.
Rare Pulmonary Disease Programs
If the company has programs in IPF, PAH, cystic fibrosis, or other rare pulmonary diseases, these programs carry unique regulatory and organizational considerations.
What to delegate:
- Rare disease clinical trial design and execution
- Orphan drug and breakthrough designation strategies
- Patient registry development and management
To whom: Dedicated rare disease clinical program directors within the CMO organization.
What the CEO retains: Decisions about entering or exiting rare pulmonary disease programs, partnership decisions for rare disease platform expansion.
Regulatory Affairs Delegation
Respiratory regulatory strategy is complicated by combination product requirements, generic and biosimilar considerations for inhaled products, and the evolving scientific standards for respiratory endpoints in clinical trials.
What to delegate:
- IND, NDA, ANDA, and BLA preparation and management
- Combination product regulatory strategy and pre-submission meetings
- Human factors regulatory submissions management
- International regulatory filings (EMA, Health Canada, regional agencies)
- Labeling development and negotiation
- Post-marketing surveillance and REMS management if applicable
To whom: Chief Regulatory Officer or VP of Regulatory Affairs, with combination product regulatory specialists on the team.
What the CEO retains: High-level FDA relationship development, final decisions on contentious regulatory strategy choices, and external communication on major regulatory milestones.
The pharma CEO guide provides a comprehensive framework for how pharma CEOs can structure regulatory delegation as part of enterprise governance.
Medical Affairs Delegation
Respiratory medical affairs must engage with a diverse physician community including pulmonologists, allergists, primary care physicians, and critical care specialists, depending on the disease areas in the company’s portfolio.
What to delegate:
- KOL identification, mapping, and engagement programs
- Medical education event development and execution
- Investigator-initiated research review and funding
- Real-world evidence study design (adherence, outcomes, health economics)
- Medical information services management
- Scientific congress planning and medical booth activities
- Patient advocacy liaison (day-to-day)
To whom: VP of Medical Affairs, with therapeutic area medical directors for asthma/COPD and rare pulmonary diseases as appropriate.
What the CEO retains: Relationships with four to six of the most prominent global respiratory thought leaders, decisions on major publication strategy for pivotal trial data, and visible participation at major respiratory congresses (ATS, ERS).
Commercial Delegation
Respiratory commercial strategy differs significantly between large-market products (where broad primary care and specialty reach is required) and rare pulmonary disease products (where specialty pharmacy and rare disease commercial models apply).
What to delegate:
- Brand marketing plan development and campaign execution
- Sales force sizing, deployment, and management (primary care and/or specialty)
- Managed care and formulary contracting (within approved parameters)
- Patient support program management
- Device training and patient education programs
- Digital health companion app development if applicable
To whom: Chief Commercial Officer, with VP-level leads for marketing, market access, and sales.
What the CEO retains: Major pricing decisions, formulary strategy for Tier 1 accounts, investor-facing commercial narrative, and competitive response strategy.
For detailed guidance on commercial delegation frameworks in pharma, the pharma commercial strategy guide covers how to structure the CEO’s commercial engagement across launch and growth phases.
Device and Digital Health Delegation
Respiratory pharmaceutical companies increasingly compete on the combination of drug efficacy and device/digital features. Connected inhalers, adherence monitoring apps, and companion digital health programs are becoming commercial differentiators. This creates a category of delegation that may not exist in other therapeutic areas.
What to delegate:
- Connected device and digital health product development
- Digital health regulatory strategy (software as a medical device considerations)
- Patient-facing app development and maintenance
- Data analytics from connected device platforms
- Digital health partnership management
To whom: VP of Device and Digital Health or equivalent, reporting to the CSO, CMO, or directly to the CEO depending on organizational structure.
What the CEO retains: Strategic decisions about device and digital health investment priorities, major partnership decisions for digital health platform development.
Managing Respiratory Portfolio Complexity
Respiratory companies often manage diverse portfolios spanning large-market and rare disease programs. The organizational challenge is ensuring that rare disease programs get adequate attention and resources without being overshadowed by larger commercial programs.
A portfolio management function - typically within the CMO or strategy organization - provides the CEO with integrated portfolio visibility and resource allocation recommendations. The CEO reviews portfolio priorities quarterly and makes capital allocation decisions; the portfolio management team handles the analytical work.
Operating Cadence for Respiratory Pharma CEOs
- Weekly: Direct report one-on-ones, written functional updates
- Monthly: Pipeline review with CMO and CSO, regulatory briefing with CRO, commercial review with CCO
- Quarterly: Full senior leadership review, board of directors meeting
- Annually: Portfolio strategy session, organizational design review
Conclusion
Respiratory pharmaceutical companies operate across a wide spectrum of complexity, from large-market inhaled products requiring broad commercial reach to rare pulmonary disease programs requiring highly specialized clinical and regulatory expertise. In both contexts, effective CEO delegation is the structural foundation for organizational performance.
Respiratory pharma CEOs who build expert functional organizations - giving genuine authority to their CMO, CSO, CRO, and CCO - create the capacity to compete effectively in one of the most demanding segments of the pharmaceutical industry. The CEO’s job is to lead the strategy, build the partnerships, and hold the team accountable. The execution belongs to the experts.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.